Pfizer Inc.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
Independent Medical Education projects that will be considered for Pfizer support will focus on increasing healthcare professional understanding of BCMA-directed therapies (BCMAxCD3 bi-specifics; BCMA-ADC; BCMA – CAR-T cells) in relapsed/refractory multiple myeloma, including:
• Mechanisms of action
• Available clinical data – efficacy insights and side effect profiles
• Scientific rationale for potential sequencing of therapies
• Use of predictive or prognostic biomarkers
• Role of sBCMA on this therapeutic class
• Therapy management
All activity formats will be considered under this RFP (live in-person, live virtual, enduring courses, online communities, digital, social, etc.)
Grant Application due date: August 31, 2021